<DOC>
	<DOCNO>NCT00560430</DOCNO>
	<brief_summary>A number study show certain blood-pressure medication ACE-inhibitors angiotensin-II-receptor blocker ( ARB ) reduce incidence diabetes mellitus type 2 . This protocol evaluate whether inflammatory mechanism mediate effect . The investigator therefore investigate effect telmisartan , potent ARB , lipid metabolism , glucose metabolism inflammation patient metabolic syndrome . Specific parameter test treatment 3 month treatment . Placebo compare 2 different dos telmisartan per day .</brief_summary>
	<brief_title>Regulation Inflammatory Parameters Telmisartan Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Abd . obesity ( BMI &gt; 25kg/m² ) waist circumference ≥95cm ( men ) , ≥80cm ( woman ) Blood pressure ≥130 mmHg ( systolic ) and/or ≥85 mmHg ( diastolic ) Triglycerides 150400 mg/dl Normal stress test Normal carotid ultrasound Normal fundoscopy Diabetes mellitus Secondary cause insulin resistance LDLcholesterol &gt; 190 mg/dl Atherosclerotic disease Blood pressure &gt; 160 mmHg ( systolic ) and/or &gt; 100 mmHg ( diastolic ) Regular alcohol consumption ( &gt; 30 g/day ) Contraindication telmisartan Antihypertensive medication Lipid lower therapy Malignancy Pregnancy Lactation Women without adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>